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Abstract Cutis laxa is a rare skin disorder characterized by
wrinkled, redundant, inelastic and sagging skin due to
defective synthesis of elastic fibers and other proteins of the
extracellular matrix. Wrinkled, inelastic skin occurs in
many cases as an acquired condition. Syndromic forms of
cutis laxa, however, are caused by diverse genetic defects,
mostly coding for structural extracellular matrix proteins.
Surprisingly a number of metabolic disorders have been
also found to be associated with inherited cutis laxa.
Menkes disease was the first metabolic disease reported
with old-looking, wrinkled skin. Cutis laxa has recently
been found in patients with abnormal glycosylation. The
discovery of the COG7 defect in patients with wrinkled,
inelastic skin was the first genetic link with the Congenital
Disorders of Glycosylation (CDG). Since then several
inborn errors of metabolism with cutis laxa have been
described with variable severity. These include P5CS,
ATP6V0A2-CDG and PYCR1 defects. In spite of the
evolving number of cutis laxa-related diseases a large part
of the cases remain genetically unsolved. In metabolic cutis
laxa syndromes the clinical and laboratory features might
partially overlap, however there are some distinct, discrim-
inative features. In this review on metabolic diseases
causing cutis laxa we offer a practical approach for the
differential diagnosis of metabolic cutis laxa syndromes.
Introduction
Cutis laxa (CL) is characterized by redundant, sagging,
inelastic and wrinkling skin (Morava et al. 2009a; van
Maldergem et al. 1989). This disorder of skin and connective
tissue can be inherited (autosomal recessive, autosomal
dominant and X-linked recessive) or acquired. Manifesta-
tions of CL occur generalized as well as local and might
improve over time in some of the patients (Morava et al.
2006). Defective elastin synthesis and structural abnor-
malities in extracellular matrix proteins leading to CL can
be further confirmed by demonstrating an abnormal
histological staining and ultrastructure in skin biopsy
(Urban et al. 2005).
Autosomal dominantcutis laxa (ADCL; MIM 123700) isa
connective tissue disorder characterized by wrinkled and
sagging inelastic skin associated with internal organ involve-
ment (van Maldergem et al. 1989). Patients are usually
diagnosed in early childhood with a mild form of cutis laxa
with some systemic involvement (hernias, cardiovascular
manifestations, gastrointestinal diverticuli and emphysema).
ADCL is genetically heterogeneous: mutations have been
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DOI 10.1007/s10545-011-9305-9reportedinthe elastin gene(ELN; MIM 130160) as well as in
the fibulin-5 gene (FBLN5; MIM 604580) (Hu et al. 2006).
Homozygous mutations in FBLN5 are associated with the
more severe form of CL with extensive systemic involve-
ment, (autosomal recessive cutis laxa type 1; ARCL1; MIM
219100).
ARCL1 is a distinct type of often lethal, generalized
connective tissue disorder with severe systemic manifes-
tations (Elahi et al. 2006). The skin manifestations affect
the whole body and are usually recognizable from birth.
Pulmonary emphysema develops in early childhood, often
leading to respiratory failure. Vascular anomalies include
arterial aneurysms causing progressive heart failure and
genitourinary tract diverticuli leading to severe infections.
Intellectual development appears to be within normal range
(Mégarbané et al. 2009).
In the majority of cases with ARCL1 the genetic defect is
not known. Mutations have been identified in the genes ELN,
FBLN5 and EFEMP2 (MIM 604633), encoding elastin,
fibulin-5 and EGF-containing fibulin-like extracellular matrix
protein 2 (Fibulin-4), respectively (Elahi et al. 2006;
Hucthagowder et al. 2006; Mégarbané et al. 2009). Arach-
nodactyly, bone fractures and aneurysms are common in
patients with EFEMP2 mutations (Hucthagowder et al.
2006). Severe respiratory involvement has been observed
related to mutations in FBLN5 and LTBP4 (Elahi et al. 2006;
Urban et al. 2009).
Autosomal recessive cutis laxa, type 2 (ARCL2A and
ARCL2B; MIM 219200 and MIM 612940) is a more benign,
genetically heterogeneous condition (Fig. 1), associated with
cutis laxa with growth and developmental delay and skeletal
anomalies (van Maldergem et al. 1989;M o r a v ae ta l .2005;
Noordam et al. 2009). Patients with ARCL2 present with
generalized cutis laxa at birth. Intellectual deficit and seizures
have been reported in older patients (Morava et al. 2009a, b).
The systemic manifestations are mild in ARCL2 and
pulmonary emphysema and cardiac anomalies are rare. The
underlying etiology in the majority of ARCL2 cases remains
unknown; in some patients a combined disorder of N- and O-
linked glycosylation (congenital disorder of glycosylation
type II) has been detected due to mutations in the ATP6V0A2
gene (MIM 611716) (Morava et al. 2005;K o r n a ke ta l .
2008). There are only a few specific clinical features that
distinguish ARCL2 patients with glycosylation defects from
those without metabolic anomalies. Mutations in the PYCR1
gene (MIM 179035) (Fig. 2) have recently been identified in
patients with ARCL2 with wrinkly skin, osteopenia and
progeroid features, and the closely related de Barsy syndrome
(DBS; MIM 219150) (Reversade et al. 2009). Mutations in
another Golgi-related gene product, GORAB, have been
found in several patients with gerodermia osteodysplastica
(GO; MIM 231070), which can be regarded as a subform of
ARCL2 (Hennies et al. 2008).
Inborn errors of metabolism such as Menkes syndrome
(MIM 309400) are also associated with cutis laxa (Fig. 1).
Fig. 1 Genetic defects related to biochemical pathways or inborn errors of
metabolism in patients with cutis laxa and their suggested pathomechanism
Fig. 2 Metabolic pathways
related to P5CS and PYCR1
defects
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Menkes disease
In 1962 Menkes described an X-linked recessive disorder later
to be known as Menkes disease (MD; MIM 309400),
characterized by kinky hair, growth retardation and progressive
neurological dysfunction with a fatal course. The characteristic
abnormality of the scalp hair is caused by a combination of
broken (trichorrhexis nodosa) and twisted (pili torti) hair of
varyingdiameterofthehairshaft(Menkesetal.1962)( F i g .3c).
Subsequently, the classical phenotype was broadened by
reporting hypothermia, skeletal anomalies and vascular
defects due to a generalized connective tissue disorder in
these patients. The physiopathology is entrapment of
copper in the intestinal mucosa due to a defective transport
mechanism, leading to systemic copper deficiency in
multiple organs, especially in the brain (Danks et al. 1972).
MD is caused by a defect in the ATP7A gene (MIM
300011) leading to dysfunction of the ATP7A protein, a
copper-transporting ATPase expressed in almost all tissues
except the liver (Vulpe et al. 1993; Chelly et al. 1993;
Mercer et al. 1993). Normally localized in the trans-Golgi
network, it supplies the excreted copper-dependent enzymes
with copper, facilitates the ATP fueled efflux in cells and the
uptake of copper in the small intestine (Yamaguchi et al.
1996; Camakaris et al. 1995). In conditions where copper is
increased it translocates to the plasma membrane and this
copper efflux restores homeostasis (Petris et al. 1996).
Dysfunction of this mechanism leads to decreased activity
of the copper-dependent enzymes and deficiency of copper
in the brain due to lack of transport across the blood-brain
barrier. Failure of these copper-transport mechanisms has
severe consequences. The classical Menkes phenotype leads
to death in the first years. Since the initial description many
o t h e rs y m p t o m sh a v eb e e na s s o c i a t e dw i t hM D( T a b l e1)a n d
besides the classical, lethal phenotype milder forms have
been described. Occipital Horn Syndrome (OHS MIM
304150 or X-linked cutis laxa), the mildest Menkes pheno-
type, manifests with cutis laxa (Fig. 3a), hernias, diverticula
of the gastrointestinal tract and bladder, tortuosity of the
arteries, hyperlaxity of the joints and skeletal anomalies. The
neurological symptoms are less severe and life expectancy is
longer than in classical Menkes disease. The most charac-
teristic feature of OHS is the formation of occipital
exostoses due to calcification of the attachments of the
trapezius and sternocleidomastoid muscles to the occip-
ital bone (Proud et al. 1996).
Fig. 3 Cutis laxa in a patient
with ARCL2 demonstrating
sagging truncal and abdominal
skin (a), characteristic facial
features and microcephaly in a
patient with COG7-CDG (b),
kinky, hypopigmented hair in
X-linked cutis laxa syndrome (c)
and downslanting palpebral fis-
sures and sagging chin in patient
with ATP6V0A2-CDG (d)
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been discovered in MD and OHS with great clinical
heterogeneity, inter- and intrafamilial (Møller et al. 2009).
Diagnosis is based on clinical features, low serum
copper and ceruloplasmin. Sequencing of the ATP7A gene
is however the diagnostic gold standard. Unfortunately,
treatment options are very limited and mostly symptomatic.
Recent studies suggest that parenteral or subcutaneous
copper administration could prolong survival in patients
with partially active ATP7A function, when initiated soon
after birth (Kaler et al. 2008).
COG7-CDG
Congenital disorders of glycosylation (CDG) form a hetero-
geneous group of inborn errors of metabolism characterized
by a defective biosynthesis of glycans. These disorders are
often multisystemic. The protein N-glycosylation disorders
can be subdivided in type I and II disorders based on the
transferrin isoelectric focusing (TIEF) pattern. There are two
main types of protein glycosylation of clinical significance:
the N-glycosylation and the O-glycosylation. N-glycosylation
starts in the cytoplasm and endoplasmatic reticulum (ER)
where an oligosaccharide is assembled on a dolichol carrier
and transferred to the nascent protein, which is then processed
in the Golgi. O-glycosylation is limited to the Golgi. Defects
in the N-glycosylation pathway generally show abnormal
plasma TIEF profiles, whereas mucin type O-glycosylation
defects leadtoabnormalisofocusingofplasmaapolipoprotein
C-III (apoC-III) (Wopereis et al. 2006).
Defects in the Conserved Oligomeric Golgi complex
(COG) are mostly responsible for the recent expansion of
novel CDG subtypes. COG7-CDG (CDG type IIe, MIM
608779) is caused by a mutation in subunit seven of the COG
complexexistingofeightsubunitsintotal(Morava et al.2007;
Ng et al. 2007; Spaapen et al. 2005;W ue ta l .2004). The
defect localized in the Golgi results in a combined N- and
O-glycosylation defect.
To date six patients with COG7-CDG, all with a fatal
outcome,havebeendescribed.Allaffectedpatientswerefrom
consanguineous descent. The clinical characteristics are
growth retardation, microcephaly (Fig. 3b), hypotonia, cutis
laxa or wrinkled skin, hepato-splenomegaly, skeletal dyspla-
sia, cardiac anomalies, recurrent infections, feeding prob-
Table 1 Clinical features in metabolic disorders associated with cutis laxa
ATP7 COG7 ATP6V0A2 PYCR1 P5CS MAP-k pathway genes
Cutis laxa + + ++ ++ + +/−
Psychomotor retardation + + + + ++ +/−
Seizures ++ + +/−− ++ / −
Neuropathy − + −− + −
Hypotonia − ++ + − ++ +
Hypertonia + −− − − −
Athetoid movements −− − ++ + −
Cobble stone-like brain defect −− ++/−− − −
Corpus callosum hypoplasia/aplasia −− − ++/−− +/−
Open fontanel/late closure −− ++ −− −
Microcephaly + ++ + +/− + −
Dysmorphic features + + ++ + + ++
Kinky, sparse hair ++ −− − − +/−
Hypopigmentation skin/nails + −− − − −
Growth delay ++ ++ + + + +
Hyperlaxity of joints + + ++ + ++ +/−
Adducted thumbs/distal arthrogryposis − ++ − ++ −−
Spontaneous bone fracture + − +/− +/− +/−−
Hernias ++ − ++ + − +/−
VSD − + −− − +/−
Spontaneous vascular ruptures + −− − − −
Hyperthermia − + −− − −
Hypothermia + −− − − −
Recurrent infections − + −− − −
Cataracts −− − +/− ++ −
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seizures and structural brain abnormalities. Liver function is
disturbed leading to elevated serum transaminases and
bilirubin (Morava et al. 2007;N ge ta l .2007; Spaapen et
al. 2005;W ue ta l .2004).
With the discovery of COG7-CDG, the first association
between cutis laxa and glycosylation was discovered (Wu et al.
2004). So far no histological evaluation is available proving
abnormal elastin structure underlying the skin anomalies in
COG7-CDG patients. It is hypothesized that hypoglycosyla-
tion of extracellular matrix proteins, elastin and/or collagen,
could be causative.
ATP6V0A2-CDG
Autosomal recessive cutis laxa type IIA (ARCL2A, Debré
type MIM 219200) and wrinkly skin syndrome (WSS; MIM
278250) are characterized by excessive skin wrinkling or
congenitalcutislaxa,intrauterinegrowthretardation,failureto
thrive, microcephaly, multiple dysmorphic features (Fig. 3d)
and a large and late closing fontanel (Morava et al. 2005).
Additionally, hypotonia, feeding problems, hyperlaxity of
joints and an abnormal fat distribution might occur (Morava
et al. 2008). The most common ocular anomalies are
strabismus and myopia. Congenital hip dislocations and
decreased bone mineral density are frequent skeletal find-
ings. Developmental delay is observed in the majority of
patients (mainly due to muscle hypotonia and joint laxity)
but brain anomalies are rare. Neurological symptoms include
psychomotor retardation, seizures, hearing loss and cobble-
stone like brain dysgenesis (Van Maldergem et al. 2008;
Morava et al. 2009b). In this unique form of cutis laxa
syndrome the skin features seem to improve over time.
The initial finding of a combined N- and O-linked
glycosylation defect in children diagnosed with ARCL2
made the first link between CDG and extracellular matrix
anomalies in cutis laxa patients (Morava et al. 2006). All
affected patients showed a type 2 pattern on transferrin
isoelectrofocusing (TIEF), abnormal isoelectrofocusing of
apolipoprotein C-III (apoC-III) and abnormal mass spec-
trometry of glycans of total serum proteins (Morava et al.
2008; Kornak et al. 2008).
In the other group of children demonstrating wrinkled
skin, a Golgi transport defect causing COG7-CDG, sup-
plied further pathogenetic evidence for the role of glyco-
sylation in the normal maturation of extracellular matrix
proteins. Consequently, CDG screening was performed in a
large group of consanguineous patients with ARCL2.
Genetic analysis led to the discovery of different loss of
function mutations in the vesicular H
+-ATPase subunit a2,
ATP6V0A2 (Kornak et al. 2008). Since then several different
mutations have been detected in WSS and ARCL2 without a
clear genotype-phenotype correlation (Hucthagowder et al.
2009). The mechanism, leading to cutis laxa in ATP6V0A2-
CDG patients has not yet been fully unraveled. Possible
theories include an abnormal transport of extracellular matrix
(ECM) proteins due to the v-ATPase related proton pump
defect (Kornak et al. 2008;G u i l l a r de ta l .2009), delayed
secretion of elastin and excessive storage of immature
compounds like tropoelastin in the Golgi (Hucthagowder et
al. 2009) and abnormal function and transport of glycosyl-
transferases leading to a hypoglycosylated state of diverse
extracellular matrix components (Kornak et al. 2008;
Hucthagowder et al. 2009).
P5CS
Δ
1-pyrroline-5-carboxylate synthase (P5CS) (Fig. 2) catal-
yses the reduction of glutamate to Δ
1-pyrroline-5-carbox-
ylate (P5C), a precursor of proline and ornithine.
Deficiency of P5CS leads to decreased levels of proline
and ornithine in some patients. Proline, apart from its role
in protein synthesis, is hypothesized to play a role in
neurotransmission. Ornithine is an important intermediate
in the urea cycle. Two isoforms of P5CS, generated by
alternative splicing, are known: the short isoform mainly
participates in arginine production in the gut whereas the
long isoform is important for proline synthesis in various
tissues (Phang et al. 1995; Valle and Simell 1995).
Deficiency of P5CS was first described in two Algerian
siblings with progressive neurodegeneration, joint laxity,
skin hyperlaxity and bilateral subcapsular cataracts.
A missense mutation, R84Q, altering a conserved
residue in the P5CS γ-glutamyl kinase domain and thereby
reducing the activity of both isoforms was found in the two
siblings (Kamoun et al. 1998; Baumgartner et al. 2000).
The clinical phenotype in P5CS deficiency (MIM 138250)
is characterized by cutis laxa, microcephaly, bilateral subcap-
sular cataract, severe mental retardation, joint laxity and
hypotonia, structural brain abnormalities, progressive neuro-
degeneration, seizures, peripheral neuropathy and dystonic
movements in hands and feet (Baumgartner et al. 2005).
Biochemically, P5CS deficiency leads to a very typical
pattern of paradoxical hyperammonemia as well as hypo-
prolinaemia and deficiency of urea cycle intermediates
(ornithine, citrulline and arginine). Two pathophysiological
explanations have been suggested for the clinical findings in
P5CS deficiency. First, protein synthesis could be impaired
in tissues depending highly on the endogenous production of
proline, for example the production of collagen in connective
tissues leading to cutis laxa (Smith and Phang 1978). But in
this case rather an Ehlers-Danlos-like phenotype should be
expected. The presence of a proline transporter in synaptic
vesicles and axon terminals of glutamatergic neurons suggest
a role of proline in neurotransmission. This might explain the
severe mental retardation in the patients (Shafqat et al. 1995).
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protecting cells from oxidative stress (Phang et al. 2008).
Errors in proline synthesis could therefore lead to develop-
mental defects through increased apoptosis. Low levels of
ornithine impair the urea cycle and thus lead to low serum
levels of citrulline and arginine, and hyperammonemia.
Following a meal, dietary arginine will temporarily restore
the urea cycle, explaining the paradoxical character of the
hyperammonemia.
Bicknell et al. described a family with four members
affected by autosomal recessive cutis laxa due to a C-terminal
P5CS missense mutation (Bicknell et al. 2008). Detailed
biochemical serum analysis only revealed mildly low
ornithine levels under fasting conditions, but no significantly
altered proline concentrations. Furthermore, the rate of
proline biosynthesis from glutamate was normal in patient
fibroblasts. In contrast, the clinical presentation was highly
similar to the previously reported cases casting doubt on the
role of proline synthesis itself in the disease mechanism.
Only a few patients have been reported, and evidence-based
treatment options are thus very limited. Trials with ornithine
treatment showed poor results (Baumgartner et al. 2005).
PYCR1
Pyrroline-5-carboxylate reductase 1 (PYCR1) catalyses the
reduction of Δ
1-pyrroline-5-carboxylate (P5C) to proline, the
final step in the synthesis of proline from glutamate (Fig. 2)
(Adams and Frank 1980). Like P5CS, it plays a role in the
biosynthesis of proline. PYCR1 is most highly expressed in
bone and skin and is localized in mitochondria (Fig. 1).
Clinical features in PYCR1 deficient individuals (MIM
179035) include cutis laxa (most pronounced on the dorsum
of hands and feet), dysmorphic features, osteopenia, distal
arthrogryposis, joint laxity, hernias, mild mental retardation,
athetoid movements and aplasia or hypoplasia of the corpus
callosum. Although hypoprolinaemia would be expected,
based on PYCR1 function, serum proline levels in PYCR1
deficient patients were within the normal range (Reversade et
al. 2009). In urine, low-normal levels were found.
Guernsey et al. (2009) described a homozygous mutation
in the PYCR1 gene, localized on chromosome 17, in five
members of two Canadian families. This missense muta-
tion, R266Q, leads to a premature termination of the
PYCR1 gene product leading to loss of function. Eight
additional mutations have been found in 35 members of 22
families. PYCR1 mutations have been found in various
cutis laxa syndrome phenotypes, including De Barsy
syndrome, Wrinkly Skin syndrome and also in ARCL2
patients, showing a similar clinical presentation as those
with ATP6V0A2 defect (Leao-Teles et al. 2010).
Upon oxidative stress PYCR1-deficient fibroblasts
showed low mitochondrial membrane potential, a disrup-
tion of the mitochondrial network, and increased apoptosis
rates. Likewise, knockdown of PYCR1 in Xenopus and
zebrafish entailed epidermal hypoplasia and blistering,
accompanied by a massive increase in apoptosis (Reversade
et al. 2009). Addition of exogenous proline did not
influence these effects observed in vitro and in vivo.
Although P5CS and PYCR1 defects are located in the same
pathway, patients with PYCR1 mutations are less severely
affected and have a better prognosis due to the absence of
neurological involvement. This can be explained by the
ubiquitous presence of a highly identical paralogue, PYCR2.
P5CS is only encoded by a single gene.
As discussed for P5CS, it is not sure that proline
synthesis plays the main role in the disease process. No
treatment is available.
RIN2
Basel-Vanagaite et al. recently described a new elastic
tissue disorder in three patients from two related consan-
guineous Israeli-Arab families (Basel-Vanagaite et al.
2009). Clinical features included soft, redundant facial
skin, macrocephaly, downslanting palpebral fissures, puffy
eyelids, sagging cheeks, everted lower lip, micrognathia
and abnormal skull morphology, gingival hypertrophy,
irregular dentition, sparse scalp hair and severe joint
hyperlaxity and scoliosis. Psychomotor development was
normal. The syndrome was termed MACS: macrocephaly,
alopecia, cutis laxa and scoliosis (MIM 613075). Genetic
analysis revealed a single base pair deletion in the RIN2
gene on chromosome 20. Afterwards a very similar
phenotype was described in three siblings from a consan-
guineous Algerian family (Syx et al. 2010). A deletion in
the RIN2 gene was found in these patients.
The gene product, the Ras and Rab interactor 2
protein, has been proven to interact with the Rab5
protein, which is required for endosomal trafficking
(Saito et al. 2002). Endosomal trafficking was not
impaired in RIN2-deficient patients, but it has been
suggested that RIN2-deficiency (MIM 610222) is respon-
sible for the phenotype through impairment of other
trafficking pathways, eg ER-to-Golgi or Golgi-to-plasma
membrane (Syx et al. 2010). Fibroblasts of the patients
reported so far showed abnormal morphology of the Golgi
apparatus with swollen cisternae and vacuole accumula-
tion. Biochemical investigations in one of the patients
showed normal plasma N-glycans and variable alterations
of the mucin type O-glycan Apolipoprotein C-III1, similar
to the profile seen in patients with abnormal Golgi-related
O-glycosylation (Albrecht et al. 2010; Wopereis et al.
2003, 2006). Besides their role for endosome functionRIN
proteins have also been described as a regulator of the Ras-
pathway. This function could explain the weak overlap
912 J Inherit Metab Dis (2011) 34:907–916between MACS syndrome and Costello syndrome (sparse
hair, prominent lips, cutis laxa) (see below).
Metabolic pathway defects described in association
with wrinkled skin or cutis laxa
Transaldolase defiency, caused by a mutation in the
TALDO1 gene (MIM 602063), presents with aortic coarc-
tation, bleeding tendency, hepatosplenomegaly, telangiecta-
sias of the skin and enlarged clitoris. Biochemical
investigations showed thrombocytopenia and elevated con-
centrations of ribitol, D-arabitol and erythritol in urine and
plasma. Recently erythronic acid was described as a novel
biomarker for this disease (Engelke et al. 2010). One of the
patients with this rare condition also showed severe cutis
laxa phenotype. So far, there is no evidence, whether the
association of TALDO1 defect and cutis laxa is a coinci-
dence (Valayannopoulos et al. 2006).
Heterozygous germline mutations in genes encoding
enzymes and regualators of the Ras-MAPK pathway cause
Noonan syndrome (MIM 163950) and the related disorders
Cardio-Facio-Cutaneous (MIM 115150), LEOPARD (MIM
151100 and 611554) and Costello syndrome (MIM 218040)
(Gelb and Tartaglia 2006). These are clinically characterized
by distinctive facial appearance, heart defects, ectodermal
abnormalities, variable cognitive defects, motor delay and
susceptibility to certain malignancies. Mutations in several
genes (PTPN11, RAF, NF, HRAS, BRAF, MEK1/2, KRAS,
SOS, SHOC2, NRAS and RAF1) have been identified in
patients, all regulating the Ras-MAPK cascade (Sarkozy et
al. 2009). Several patients have been reported with wrinkled
skin and cutis laxa, especially in the inguinal, axillary
regions, and affecting the hands and feet, caused by diverse
mutations associated with Noonan, Cardio-Facio-Cutaneous
or Costello syndromes (Kleefstra et al. 2011).
Gerodermia osteodysplastica (MIM 231070) is a clinical
syndrome first described in 1950 by Bamatter et al.
(Bamatter et al. 1950). It is characterized by lax, wrinkled
skin, joint hyperlaxity, progeroid facial appearance, severe
osteoporosis, malar and mandibular hypoplasia and growth
retardation. The disorder is also known as ‘Walt Disney
dwarfism’ due to the typical facial features (Bamatter et al.
1950). In a recent study by Hennies et al., genetic analysis
of affected individuals from 13 families revealed nine
pathogenic mutations in the GORAB (SCYL1BP1) gene
(Hennies et al. 2008). The gene product GORAB interacts
with Rab6, a protein involved in intracellular trafficking
(Grigoriev et al. 2007). Interestingly, Rab6 has been
demonstrated to interact with the conserved oligomeric
Golgi complex (COG) (Sun et al. 2007). However,
glycosylation defects have not been observed in GORAB
deficiency (MIM 607983) (Hennies et al. 2008).
Discussion
Cutis laxa and wrinkled skin are frequently associated with
diverse metabolic conditions. The majority of inborn errors
presenting with cutis laxa are related to abnormal Golgi
function and frequently related to transport defects and
abnormal protein glycosylation. Most of these syndromes
have both characteristic biochemical and clinical markers
facilitating timely diagnosis. Patients with X-linked cutis
laxa share the facial features and late closure of the fontanel
with ATP6V0A2-related ARCL2, however they also present
with the pathognomic radiological features of frontal horns,
as well as abnormal hair growth and severe muscle
involvement. In ATP6V0A2, failure to thrive, transient
feeding problems and the eventual presence of cobble-stone
like brain malformations are helpful in the diagnosis.
Table 2 Biochemical features in metabolic disorders associated with cutis laxa
ATP6V0A2 COG7 ATP7 PYCR1 P5CS MAP-k pathway genes
Abnormal TIEF + + −− −−
Abnormal ApoC-III IEF + + −− −−
Decreased serum copper −− + −− −
Decreased serum ceruloplasmin −− + −− −
Elevated serum lactic acid +/− +/−− +/−−+/−
Elevated serum ammonia −− − − +( −) −
Decreased serum proline −− − − +( −) −
Decreased serum citrulline −− − − +( −) −
Other aminoacids −− − − − Increased alanine +/−
Endocrine abnormailties +/−− − − − −
Liver dysfunction +/− ++ −− −−
Elevated serum creatine kinase − ++ −− −+/−
J Inherit Metab Dis (2011) 34:907–916 913Patients with COG7-CDG have heart malformations, a less
severe skin involvement and more severe microcephaly.
Disorders of the MAP kinase pathway have distinct
dysmorphic features, short stature and other ectodermal
anomalies, like slow hair and nail growth. This is in many
ways similar to the ectodermal features of patients with a
RIN2 defect. PYCR1 mutation carriers have characteristic
features as well, including neonatal progeria, corpus
callosum agenesis, arthrogryposis and abnormal move-
ments. These symptoms are mostly absent in other types
of cutis laxa.
COG7-CDG and ATP6V0A2-CDG are combined N- and
O-linked glycosylation disorders (patients are demonstrat-
ing an abnormal TIEF and apo-CIII IEF). Menkes disease
and X-linked cutis laxa have abnormal copper metabolism
leading to easily detectable abnormalities in serum and
urine but normal TIEF and apoC-III IEF. Patients with
RIN2 defect have also normal serum TIEF pattern but have
been associated with abnormal O-glycosylation (Albrecht et
al. 2010).
Contrary to patients with Golgi system-related cutis laxa
forms, those with PYCR1 and MAP kinase pathway defects
show no glycosylation abnormalities. In some of these
children mild mitochondrial dysfunction has been observed,
but usually they do not manifest metabolic markers of
mitochondrial disease.
The clinical finding of wrinkled skin or cutis laxa
appears to have a growing significance due to its
occurrence in several inborn errors. Although the pathoge-
netic explanation is not completely understood in many
cases, we suggest that the finding of wrinkled skin in a
child with developmental delay should evoke detailed
metabolic evaluation. The initial step is to perform a skin
biopsy for histology and electron microscopy in order to
differentiate between collagen and elastin abnormalities.
The combination of elastin fragmentation in the skin biopsy
and abnormalities of the TIEF and/or Apo C-III IEF might
lead directly to the diagnosis of ATP6V0A2-CDG. Less
severe elastin abnormalities are suggestive for COG7-CDG.
Copper and ceruloplasmin are reliable screening tools when
X-linked cutis laxa or Menkes Disease are suspected.
Routine metabolic screening for ammonia, lactic acid and
serum amino acid levels can give clues about the possible
underlying metabolic disease, especially in P5CS, PYCR1
or MAP kinase defects (Table 2). More specific laboratory
investigations or direct mutation analysis can be performed
based on pathognomic clinical features and discriminative
biochemical results (Tables 1 and 2).
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